Catalyst Pharmaceutical Partners To Present At Aegis Capital 2013 Healthcare Conference

CORAL GABLES, Fla., Sept. 25, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will present at the Aegis Capital 2013 Healthcare Conference being held at The Encore at Wynn Las Vegas, September 25-28. The presentation is scheduled for Friday, September 27 th at 1:00 pm (PDT). The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette Syndrome.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including the timing of completion of Catalyst's currently ongoing Phase III trial of Firdapse™, whether the Phase III trial will be successful, whether the receipt of breakthrough therapy designation for Firdapse™ will expedite the development and review of Firdapse™ by the FDA or the likelihood that the product will be found to be safe and effective, whether an NDA for Firdapse™ will ever be accepted for filing by the FDA, the timing of any such NDA filing or acceptance, whether any of Catalyst's product candidates will ever be approved for commercialization or successfully commercialized, and those other factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2012 and other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.  
CONTACT: For Further Information Contact:         Patrick J. McEnany         Catalyst Pharmaceutical Partners         Chief Executive Officer         (305) 529-2522         pmcenany@catalystpharma.com                  Melody Carey         Rx Communications Group         Co-President         (917) 322-2571         mcarey@rxir.com

If you liked this article you might like

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

One Reason Why Catalyst Pharmaceuticals (CPRX) Stock Is Jumping Today

These 7 Stocks Under $10 Could Make You a Lot of Money

Anavex Plays the Orphan Drug Stock Promotion Game

Catalyst Pharmaceuticals (CPRX) Stock Plunges After FDA 'Refusal to File' Letter